| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||
|
DrEaMzZz
Member |
12-Aug-2013 09:57
|
||||
|
x 0
x 0 Alert Admin |
It's time for company to activate share buy-back scheme Liao....
|
||||
| Useful To Me Not Useful To Me | |||||
|
Octavia
Elite |
12-Aug-2013 09:55
|
||||
|
x 0
x 0 Alert Admin |
The 1QFY14 net profit of US$12.1m (-63% yoy) was significantly below expectations. Revenue declined 11% yoy to US$76.6m, while gross profits dropped 17%. The results were adversely affected by inventory drawdowns across its channels in China in view of looming price cuts, resulting in DES revenues declining 6% yoy. Licensing revenues from Japan were also down 33% yoy. Deutsche sees further erosion in royalty income in FY14, given continued competition in Japan, in particular, Abbott launched its Xience Xpedition in Japan in Jul. Expects further margin erosion due to, i) increasing costs in Japan, ii) integration of acquired business, and ii) increase sales and marketing costs. Deutsche lowers TP to $1 (from $1.15), based on 13x FY15e P/E. Maintains Hold rating. OCBC downgrades to Hold from buy, slashes TP to $0.96 from $1.60. Expects some near term selling pressure. CS cuts TP to $1.43 (from $1.80), but maintains Outperform rating. Nomura keeps at Buy with TP $1.80. | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Tomique
Master |
12-Aug-2013 09:46
|
||||
|
x 0
x 0 Alert Admin |
Any followers? I came out long ago and still don't find any interest to enter yet. Those who got it high can either do HIWTYL or buy and buy until it reaches the bottom, catching falling knives and needing alot of capital.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Winson
Senior |
12-Aug-2013 09:40
|
||||
|
x 0
x 0 Alert Admin |
Lelong for this counter. Vomit blood day,
|
||||
| Useful To Me Not Useful To Me | |||||
|
fortunecat
Member |
12-Aug-2013 09:14
|
||||
|
x 0
x 0 Alert Admin |
officially penny stock... | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
DrEaMzZz
Member |
12-Aug-2013 09:02
|
||||
|
x 0
x 0 Alert Admin |
Drop so much today... | ||||
| Useful To Me Not Useful To Me | |||||
|
Tomique
Master |
11-Aug-2013 14:19
|
||||
|
x 0
x 0 Alert Admin |
Why not use " heads I win, tails you lose" strategy? Sell a little at a time, so that if it goes the wrong way (up) you still have stocks, maybe can make back some money if it climbs strongly. If it continues to fall as you sell, then when it reaches your target price to buy back, then buy back and make sure you really buy back!!. This HIWTYL system is quite effective and can save you alot of nightmares and good for those who got stuck at higher prices.. Cheers. Hehe...
|
||||
| Useful To Me Not Useful To Me | |||||
|
New123
Elite |
08-Aug-2013 12:17
|
||||
|
x 0
x 0 Alert Admin |
down trend . Has to bounce up to $1.00 & above , if not better wait for the right direction? | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Peter_Pan
Supreme |
08-Aug-2013 11:31
Yells: "did you order dunkin' donuts" |
||||
|
x 0
x 0 Alert Admin |
Biotechnology company Biosensors’ (SGX: B20) reported an 11% decline in first-quarter sales to US$76.7m. Profits fell some 63% to US$12.1m.
The company’s main business activity lies in the manufacture of various types of drug-eluting stents (DES), which are medical device used to unclog blocked arteries. The company splits its revenue into four segments, namely, Critical Care, Interventional Cardiology, Cardiac Diagnostic and Licensing & Royalties. Biosensor’s top-line decline was mainly due to a drop in revenues from Interventional Cardiology and Licensing & Royalties, both of which are the main revenue drivers for the company. The former made up 79% of the company’s total sales while the latter accounted for 17%. Interventional Cardiology’s sales for the quarter slid 7.3% to US$60.9m from a year ago mainly due to a slowdown in DES sales in China. That in turn, was the result of the company’s intentional reduction in the inventory levels of distributors in China because of “on-going and upcoming tender activities.” The company’s other DES markets in the Europe, Middle East & Africa (EMEA) and Asia Pacific regions all saw “strong, double-digit sales growth.” Licensing & Royalties revenue, where Biosensors licenses its DES technology to others, was down by 32.7% to US$11.6m. Critical Care brought in US$3.43m in sales, up a smidgen from US$3.34m in the previous year. Finally, Cardiac Diagnostic had US$706,000 in sales for the quarter. It is a new segment for Biosensors, and is the result of a consolidation of Spectrum Dynamics’ business. Spectrum Dynamics is a company that does cardiac imaging systems and was acquired by Biosensors for US$51m in May this year. Biosensor’s CEO, Dr Jack Wang, had this to say regarding the acquisition: “The integration process of our recently acquired business, [Spectrum Dynamics], is well on track. We are excited about the recent Japanese regulatory approval of its D-SPECT system and we remain confident of our ability to unlock the potential of this business.” The company’s profits fell proportionately more than the decline in revenues which suggests a compression in net profit margins. There are three reasons for this. Firstly, gross margins fell from 85% to 79%. Biosensors had entered into an agreement with Terumo Corporation in Japan to distribute Nobori DES last year and the distribution activity this quarter was one of the reasons for the fall in gross margins. The consolidation of Spectrum Dyanmics’ businesses also ate into Biosensor’s gross profits as Cardiac Diagnostics carry inherently lower margins. Secondly, Biosensor had spent US$26.6m on sales & marketing expenses for the quarter, an increase of 19.3% from a year ago. Finally, there was a 121% year-on-year increase in interest expenses to US$3.4m. The increase was mainly due to US$240m worth of debt that Biosensors issued on Jan 2013. Those loans are due for repayment after four years and carry an interest rate of 4.875% per year. The three reasons were the main causes for Biosensor’s lower net profit margins. Biosensors’ balance sheet remains robust with a total debt load of US$273m and a cash hoard worth US$546m. The company is satisfied with the amount of cash on hand and with “continued improvement in [its] operating performance” in the horizon, there are no plans currently for future fund raising activities. The company has forecast a 15% year-on-year growth in revenues for the year. It expects sales continuing to climb in the EMEA and Asia Pacific regions and it is confident that DES sales in China will pick up in rest of the year. In addition, Biosensors also expects the Spectrum Dynamics acquisition to provide new markets for the company. Shares of Biosensors closed at S$0.975 on Wednesday, which represents a trailing price-to-earnings ratio of 14 and a dividend yield of 2.6% based on last year’s full-year pay-out. |
||||
| Useful To Me Not Useful To Me | |||||
|
Peter_Pan
Supreme |
08-Aug-2013 11:27
Yells: "did you order dunkin' donuts" |
||||
|
x 0
x 0 Alert Admin |
MEDICAL device manufacturer Biosensors Group International announced a 63 per cent fall in net profit to US$12.1 million (S$15.3 million) for its first quarter ended June 30.
Lower profit was due to a combination of lower revenue, higher cost of sales and higher sales and marketing expenses. Revenue was down 11 per cent to US$76.7 million. The group is guiding for revenue for the fiscal year ending Mar 31, 2014, to grow by 15 per cent, driven by growth for drug-eluting stent sales and an expectation that China sales will recover. |
||||
| Useful To Me Not Useful To Me | |||||
|
Dividend_Warrior
Senior |
08-Aug-2013 08:55
Yells: "I am getting $1100 per month in dividends :)" |
||||
|
x 0
x 0 Alert Admin |
Boustead has Bionsensor bonds.......lol | ||||
| Useful To Me Not Useful To Me | |||||
|
Winson
Senior |
07-Aug-2013 23:37
|
||||
|
x 0
x 0 Alert Admin |
just one day kenna burnt till both hand all bubble ready and still holding to it, hope monday will rebound. | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Peter_Pan
Supreme |
07-Aug-2013 21:47
Yells: "did you order dunkin' donuts" |
||||
|
x 0
x 0 Alert Admin |
May either rebound or drop next week. 0.96 must hold, if not | ||||
| Useful To Me Not Useful To Me | |||||
|
Farmer
Master |
07-Aug-2013 21:37
|
||||
|
x 0
x 0 Alert Admin |
Management guidance of 15% revenue grow this year still intact. Share price may rebound in due course, believe worst is over? | ||||
| Useful To Me Not Useful To Me | |||||
|
Stocky901
Member |
07-Aug-2013 20:54
|
||||
|
x 0
x 0 Alert Admin |
Company will activate share buy back soon as it's already been approved. Be patient, don't kill yourself unnecessarily ok.
|
||||
| Useful To Me Not Useful To Me | |||||
|
cycy818
Member |
07-Aug-2013 20:41
|
||||
|
x 0
x 0 Alert Admin |
omg. regret didn't listen to yiming2000 advice..... bleeding now....... first thing to do on monday... cut lost..... |
||||
| Useful To Me Not Useful To Me | |||||
|
Dreamy
Member |
07-Aug-2013 20:05
|
||||
|
x 0
x 0 Alert Admin |
hope one day it would be a potential takeover target from big pharmaceutical companies.....
|
||||
| Useful To Me Not Useful To Me | |||||
|
Stocky901
Member |
07-Aug-2013 19:53
|
||||
|
x 0
x 0 Alert Admin |
Will rebound next week due to stock oversold. Don't sell cheap to sortist. Keep for few quarters if you have holding power.
|
||||
| Useful To Me Not Useful To Me | |||||
|
bishan22
Elite |
07-Aug-2013 19:52
|
||||
|
x 0
x 0 Alert Admin |
No company buy back. Bleed till no blood.
|
||||
| Useful To Me Not Useful To Me | |||||
|
edchai
Senior |
07-Aug-2013 19:51
|
||||
|
x 0
x 0 Alert Admin |
Financial results no good le ... can rebound ? | ||||
| Useful To Me Not Useful To Me | |||||